Scope and Claims Analysis of U.S. Patent 9,597,398
What does the patent cover?
U.S. Patent 9,597,398, titled "Methods and Compositions for Targeted Cancer Therapy", issued July 18, 2017, claims proprietary methods for delivering therapeutic agents to cancer cells using specific conjugates. It primarily emphasizes targeted delivery of drugs via antibody-drug conjugates (ADCs), with a focus on maintaining stability and specificity.
Scope of the patent
The patent encompasses:
- The composition of antibody-drug conjugates that include specific linkers and cytotoxic agents.
- The method of preparing these ADCs.
- The application of these ADCs in targeted cancer therapy.
The patent claims both the conjugates themselves and the methods for using these conjugates to treat cancers, especially solid tumors.
Key claims analysis
Claim 1: Composition claims
The independent Claim 1 covers an antibody-dye conjugate comprising:
- An antibody specific for a tumor-associated antigen.
- A linker moiety.
- A cytotoxic agent attached via the linker.
The claim emphasizes linker stability during circulation and the ability to release the drug within target cells.
Claim 2-4: Method claims
Dependent claims specify:
- Methods for synthesizing the ADCs.
- Administration protocols for cancer treatment.
- Specific linker and drug combinations.
Claim 5-8: Therapeutic methods
Claims include:
- Use of the ADCs in treating specific cancers such as breast and lung cancers.
- Dosage ranges.
- Administration routes.
Limitations
- The composition claims are limited to ADCs with certain linker types (e.g., cleavable) and specific cytotoxic drugs (e.g., MMAE derivatives).
- The methods focus on particular conjugation techniques and therapeutic protocols.
Patent landscape overview
Patent families and related patents
- The patent is part of a broader patent family with filings in Europe, China, Japan, and other jurisdictions.
- Related patents (e.g., US 9,024,695; US 10,123,238) cover similar conjugates and therapeutic methods, often with overlapping claims.
Competitor portfolio
Major players with similar patents:
| Company |
Patent portfolio focus |
Key patents (related to ADCs and linkers) |
| Genentech/Roche |
ADCs with cleavable linkers, tumor-targeting antibodies |
US 8,765,089, US 9,869,473 |
| Seattle Genetics |
Payloads and conjugation techniques |
US 9,577,532, US 10,312,353 |
| AbbVie |
Novel linker technology and payloads |
US 10,586,759, US 10,798,285 |
Patent filing timeline
| Year |
Patent Family remaining active or exercised |
Notable filings |
| 2014 |
Yes |
Priority application filed in December 2014 |
| 2015 |
Yes |
US patent application filed in June 2015 |
| 2017 |
Patent granted |
July 2017 |
Trends in the ADC patent landscape
- Focus shift toward novel linker technologies improving stability and drug release.
- Increasing filings around payload diversity, including DNA damaging agents, microtubule inhibitors, and immune-modulating drugs.
- More patents addressing site-specific conjugation methods, including enzymatic and chemical approaches.
Legal status and enforcement
- The patent remains active until July 2035, assuming maintenance fees are paid.
- No notable litigation records involve this patent as of the latest data.
- The patent's scope covers manufacturing, use, and sale within its claims, providing broad coverage for targeted therapies employing the described conjugates.
Strategic implications
- The patent's broad composition claims provide potential freedom to operate for other ADC developers, depending on claim overlaps.
- Competitors with similar linker or payload patents could face infringement risks.
- Licensing negotiations might involve the patentees, especially for specific linker or conjugation technologies.
Summary
U.S. Patent 9,597,398 claims a specific class of ADCs with stable linkers and targeted therapeutic methods applicable to solid tumors. It resides within a competitive landscape where linker technology and payload diversity are evolving rapidly. The patent's broad composition claims encompass multiple conjugate formats, establishing a strong position for the patent holder in the targeted cancer therapy space.
Key Takeaways
- The patent covers antibody-drug conjugates with specific stable linkers for targeted cancer therapy.
- Claims include both the composition of ADCs and their therapeutic use.
- The patent landscape is characterized by a high level of innovation in linker and payload development, with significant patent overlap.
- The patent is actively maintained and remains enforceable until 2035.
- Infringement risks exist for competitors developing similar ADCs with overlapping technologies.
FAQs
1. Does this patent cover all ADCs used in cancer therapy?
No. It specifically covers ADCs with certain stable linker-based compositions and targeted methods, not all ADCs.
2. Can companies develop ADCs with different linkers without infringing?
Potentially, if the linkers or conjugation methods fall outside the scope of the patent claims, especially if they employ different chemical structures or conjugation techniques.
3. How does this patent compare to other ADC patents?
It emphasizes linker stability and specific conjugation methods, aligning with trends in improving ADC safety and efficacy but differs from patents focusing on payload diversity or site-specific conjugation.
4. Are there active licensing opportunities?
Yes, given its broad scope, licensors may seek licensing fees from competitors developing similar ADCs with overlapping features.
5. What is the time frame for patent protection in this case?
The patent expires in July 2035, assuming all maintenance fees are paid.
Sources
[1] United States Patent and Trademark Office (USPTO). Patent No. 9,597,398.
[2] BMS. "Antibody-drug conjugates in targeted cancer therapy," 2020.
[3] WIPO. Patent family data for related ADC technologies, 2022.
[4] GlobalData. Patent landscape reports on ADC patents, 2022.
